癌症试验中翻译版患者报告结局测量工具使用的系统综述
该系统综述审查了注册于英国国家卫生研究院研究组合的癌症临床试验方案与发表文献,评估招募、族裔数据纳入及翻译版患者报告结局测量工具的使用情况,并对44名国际利益相关者进行半结构化访谈。访谈识别了族裔多样性招募的障碍及促进因素,利益相关者对翻译版工具使用意见不一。
要点
- 癌症试验中族裔数据报告率仅17%,族裔招募比例低至13%。
- 多中心多国试验未报告使用翻译版患者报告结局测量工具。
- 利益相关者对翻译版工具使用及招募策略意见存在分歧。
核心结论
- 使用患者报告结局作为主要或次要结局的临床试验需提高透明度。
- 方案与发表文献应证明招募对多样人群可及,并通过试验设计、招募策略及适当使用测量工具促进。
- 癌症临床试验中使用翻译版患者报告结局测量工具时应明确说明。
研究设计与样本
- 系统综述审查注册于英国国家卫生研究院研究组合的癌症临床试验方案和/或发表文献,这些试验使用患者报告结局终点。
- 对关键利益相关者进行半结构化访谈,探讨优化患者报告结局试验设计、多样招募与报告及翻译版工具使用的障碍与促进因素。
主要发现
- 8项(57%)研究为多中心和多国研究,但无一报告使用翻译版患者报告结局测量工具,尽管7项(88%)研究有可用翻译版工具。
- 访谈识别了族裔多样性招募的感知障碍,包括参与者参与度、族裔与研究问题的相关性、患者报告结局的突出性及减少研究者负担的需求。
- 利益相关者对翻译版患者报告结局测量工具的使用、试验设计影响及招募策略对多样招募的影响持不同意见。
临床怎么用
- 临床试验方案与发表文献应明确报告招募是否对多样人群可及。
- 设计试验时应考虑使用适当翻译版患者报告结局测量工具以减少缺失数据和样本流失。
- 使用翻译版患者报告结局测量工具时应在方案和发表中明确说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer trial results. PRO data collection should include appropriately translated patient-reported outcome measures (PROMs) to minimise missing data and sample attrition. METHODS: Protocols and/or publications from cancer clinical trials using a PRO endpoint and registered on the National Institute for Health Research Portfolio were systematically reviewed for information on recruitment, inclusion of ethnicity data, and use of appropriately translated PROMs. Semi-structured interviews were conducted with key stakeholders to explore barriers and facilitators for optimal PRO trial design, diverse recruitment and reporting, and use of appropriately translated PROMs. RESULTS: Eighty-four trials met the inclusion criteria, only 14 (17%) (n = 4754) reported ethnic group data, and ethnic group recruitment was low, 611 (13%). Although 8 (57%) studies were multi-centred and multi-national, none reported using translated PROMs, although available for 7 (88%) of the studies. Interviews with 44 international stakeholders identified a number of perceived barriers to ethnically diverse recruitment including diverse participant engagement, relevance of ethnicity to research question, prominence of PROs, and need to minimise investigator burden. Stakeholders had differing opinions on the use of translated PROMs, the impact of trial designs, and recruitment strategies on diverse recruitment. Facilitators of inclusive research were described and examples of good practice identified. CONCLUSIONS: Greater transparency is required when PROs are used as primary or secondary outcomes in clinical trials. Protocols and publications should demonstrate that recruitment was accessible to diverse populations and facilitated by trial design, recruitment strategies, and appropriate PROM usage. The use of translated PROMs should be made explicit when used in cancer clinical trials.
引用
- Slade AL, Retzer A, Ahmed K, et al. Systematic review of the use of translated patient-reported outcome measures in cancer trials. Trials. 2021. PMID: 33902699. doi:10.1186/s13063-021-05255-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。